Intellia Therapeutics, Inc. (NTLA) NASDAQ
$20.24 0.12 (0.60%)
Market Cap: $2.06B
As of 09/11/24 04:00 PM EDT. Market closed.
Intellia Therapeutics, Inc. (NTLA)
NASDAQ
$20.24
0.12 (0.60%)
Market Cap: $2.06B
As of 09/11/24 04:00 PM EDT. Market closed.
Add to Portfolio
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. John M. Leonard M.D.
Full Time Employees
526
CEO Compensation (Base)
$630,000
CEO Compensation (Total)
$10.10M
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. John M. Leonard M.D.
Full Time Employees
526
CEO Compensation (Base)
$630,000
CEO Compensation (Total)
$10.10M
Address
40 Erie Street, MA, Cambridge, 02139.
PRICE CHART FOR INTELLIA THERAPEUTICS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$19.79
Previous Close
$20.12
Days Range
$19.21 - $20.29
52 week range
$19.21 - $37.16
Volume
1,300,275
Avg. Volume (30 days)
1,475,254
Market Cap
$2.06B
Dividend Yield
-
P/E
(3.69)
Shares Outstanding
101,579,000
Open
$19.79
Previous Close
$20.12
Days Range
$19.21 - $20.29
52 week range
$19.21 - $37.16
Volume
1,300,275
Avg. Volume (30 days)
1,475,254
Market Cap
$2.06B
Dividend Yield
-
P/E
(3.69)
Shares Outstanding
101,579,000
FINANCIAL STATEMENTS FOR INTELLIA THERAPEUTICS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR INTELLIA THERAPEUTICS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Clark Eliana | EVP, Chief Technical Officer | Jul 01, 2024 | Sale | $22.93 | 405 | 9,287 | 71,470 | Jul 03, 2024, 01:15 PM |
| Verwiel Frank | Director | Jun 17, 2024 | Sale | $25.00 | 1,505 | 37,625 | 17,948 | Jun 20, 2024, 05:00 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Jan 08, 2024 | Sale | $28.87 | 2,275 | 65,682 | 44,594 | Jan 10, 2024, 04:15 PM |
| LEONARD JOHN M | President and CEO | Jan 03, 2024 | Sale | $29.46 | 19,223 | 566,310 | 846,486 | Jan 05, 2024, 04:51 PM |
| Lebwohl David | EVP, Chief Medical Officer | Jan 03, 2024 | Sale | $29.46 | 5,843 | 172,135 | 54,372 | Jan 05, 2024, 04:50 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Jan 03, 2024 | Sale | $29.46 | 5,532 | 162,973 | 46,202 | Jan 05, 2024, 04:50 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Jan 03, 2024 | Sale | $29.46 | 5,365 | 158,053 | 40,585 | Jan 05, 2024, 04:49 PM |
| Hicks Derek | EVP, Chief Business Officer | Jan 03, 2024 | Sale | $29.46 | 3,877 | 114,216 | 36,987 | Jan 05, 2024, 04:46 PM |
| BASTA JAMES | EVP, General Counsel | Jan 03, 2024 | Sale | $29.46 | 3,805 | 112,095 | 51,474 | Jan 05, 2024, 04:45 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jan 03, 2024 | Sale | $29.50 | 4,608 | 135,954 | 45,146 | Jan 05, 2024, 04:44 PM |
| Bhanji Muna | Director | Oct 31, 2023 | Sale | $23.90 | 265 | 6,333 | 11,996 | Nov 02, 2023, 04:42 PM |
| Bhanji Muna | Director | Jul 31, 2023 | Sale | $42.33 | 265 | 11,217 | 12,261 | Aug 02, 2023, 05:19 PM |
| Bhanji Muna | Director | Jul 06, 2023 | Sale | $39.30 | 1,867 | 73,373 | 12,526 | Jul 10, 2023, 05:21 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jul 03, 2023 | Sale | $40.51 | 360 | 14,584 | 45,146 | Jul 06, 2023, 03:34 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jun 20, 2023 | Option Exercise | $12.27 | 5,000 | 61,350 | 50,146 | Jun 22, 2023, 05:52 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jun 20, 2023 | Sale | $45.00 | 5,000 | 225,000 | 45,146 | Jun 22, 2023, 05:52 PM |
| BASTA JAMES | EVP, General Counsel | Mar 02, 2023 | Sale | $43.88 | 1,088 | 47,741 | 55,279 | Mar 03, 2023, 05:10 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Jan 05, 2023 | Sale | $38.48 | 2,330 | 89,659 | 18,318 | Jan 06, 2023, 05:39 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Jan 04, 2023 | Sale | $37.21 | 2,508 | 93,323 | 19,959 | Jan 06, 2023, 05:39 PM |
| LEONARD JOHN M | President and CEO | Jan 04, 2023 | Sale | $37.21 | 6,673 | 248,302 | 766,825 | Jan 06, 2023, 05:32 PM |
| Hicks Derek | EVP, Chief Business Officer | Jan 04, 2023 | Sale | $37.21 | 1,812 | 67,425 | 17,306 | Jan 06, 2023, 05:29 PM |
| Lebwohl David | EVP, Chief Medical Officer | Jan 04, 2023 | Sale | $37.21 | 2,574 | 95,779 | 25,687 | Jan 06, 2023, 05:26 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Jan 04, 2023 | Sale | $37.21 | 2,427 | 90,309 | 15,404 | Jan 06, 2023, 05:23 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jan 04, 2023 | Sale | $37.21 | 1,692 | 62,959 | 14,473 | Jan 06, 2023, 05:21 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jan 03, 2023 | Sale | $34.48 | 231 | 7,965 | 16,165 | Jan 06, 2023, 05:21 PM |
| Clark Eliana | EVP, Chief Technical Officer | Jul 01, 2022 | Sale | $51.74 | 105 | 5,433 | 16,165 | Jan 06, 2023, 05:21 PM |
| BASTA JAMES | EVP, General Counsel | Jan 04, 2023 | Sale | $37.21 | 1,138 | 42,345 | 19,559 | Jan 06, 2023, 05:19 PM |
| LEONARD JOHN M | President and CEO | Jan 01, 2022 | Sale | $112.25 | 2,493 | 279,852 | 724,660 | Mar 04, 2022, 09:07 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Jan 01, 2022 | Sale | $112.25 | 1,148 | 128,863 | 4,815 | Mar 03, 2022, 08:03 PM |
| Lebwohl David | EVP, Chief Medical Officer | Jan 01, 2022 | Sale | $112.24 | 1,051 | 117,964 | 10,922 | Mar 03, 2022, 08:00 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Jan 01, 2022 | Sale | $112.24 | 1,013 | 113,699 | 2,049 | Mar 03, 2022, 07:38 PM |
| Lebwohl David | EVP, Chief Medical Officer | Nov 05, 2021 | Option Exercise | $12.62 | 2,400 | 30,288 | 11,114 | Nov 09, 2021, 06:08 PM |
| Lebwohl David | EVP, Chief Medical Officer | Nov 05, 2021 | Sale | $132.72 | 2,400 | 318,535 | 9,914 | Nov 09, 2021, 06:08 PM |
| Lebwohl David | EVP, Chief Medical Officer | Oct 14, 2021 | Option Exercise | $12.62 | 2,400 | 30,288 | 11,114 | Oct 15, 2021, 07:02 PM |
| Lebwohl David | EVP, Chief Medical Officer | Oct 14, 2021 | Sale | $128.44 | 2,400 | 308,249 | 10,563 | Oct 15, 2021, 07:02 PM |
| Crowley John F | Director | Oct 11, 2021 | Option Exercise | $18.83 | 2,500 | 47,075 | 4,594 | Oct 13, 2021, 04:15 PM |
| Crowley John F | Director | Oct 11, 2021 | Sale | $119.55 | 2,500 | 298,875 | 2,094 | Oct 13, 2021, 04:15 PM |
| Crowley John F | Director | Oct 05, 2021 | Option Exercise | $18.83 | 10,000 | 188,300 | 12,094 | Oct 07, 2021, 05:41 PM |
| Crowley John F | Director | Oct 05, 2021 | Sale | $130.54 | 10,000 | 1,305,391 | 10,814 | Oct 07, 2021, 05:41 PM |
| Lebwohl David | EVP, Chief Medical Officer | Sep 24, 2021 | Option Exercise | $12.62 | 7,923 | 99,988 | 8,714 | Sep 27, 2021, 04:15 PM |
| Lebwohl David | EVP, Chief Medical Officer | Sep 21, 2021 | Option Exercise | $12.62 | 2,400 | 30,288 | 3,191 | Sep 23, 2021, 05:48 PM |
| Lebwohl David | EVP, Chief Medical Officer | Sep 21, 2021 | Sale | $149.81 | 2,400 | 359,544 | 791 | Sep 23, 2021, 05:48 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Sep 07, 2021 | Option Exercise | $14.58 | 3,482 | 50,768 | 3,482 | Sep 09, 2021, 05:38 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Sep 07, 2021 | Sale | $180.12 | 3,482 | 627,178 | 0 | Sep 09, 2021, 05:38 PM |
| LEONARD JOHN M | President and CEO | Aug 31, 2021 | Option Exercise | $14.58 | 37,833 | 551,605 | 757,138 | Sep 01, 2021, 08:21 PM |
| LEONARD JOHN M | President and CEO | Aug 30, 2021 | Option Exercise | $14.23 | 38,804 | 552,031 | 758,109 | Sep 01, 2021, 08:21 PM |
| LEONARD JOHN M | President and CEO | Sep 01, 2021 | Option Exercise | $21.62 | 44,735 | 967,000 | 764,040 | Sep 01, 2021, 08:21 PM |
| LEONARD JOHN M | President and CEO | Aug 30, 2021 | Sale | $155.95 | 38,804 | 6,051,353 | 756,054 | Sep 01, 2021, 08:21 PM |
| LEONARD JOHN M | President and CEO | Sep 01, 2021 | Sale | $170.00 | 44,735 | 7,604,950 | 719,305 | Sep 01, 2021, 08:21 PM |
| LEONARD JOHN M | President and CEO | Aug 31, 2021 | Sale | $155.00 | 37,833 | 5,864,115 | 719,305 | Sep 01, 2021, 08:21 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Aug 30, 2021 | Option Exercise | $14.01 | 97,000 | 1,359,300 | 99,391 | Sep 01, 2021, 07:34 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Aug 30, 2021 | Sale | $154.83 | 97,000 | 15,018,055 | 83,552 | Sep 01, 2021, 07:34 PM |
| Lebwohl David | EVP, Chief Medical Officer | Aug 30, 2021 | Option Exercise | $12.62 | 2,400 | 30,288 | 3,191 | Sep 01, 2021, 07:32 PM |
| Lebwohl David | EVP, Chief Medical Officer | Aug 30, 2021 | Sale | $158.04 | 2,400 | 379,300 | 2,991 | Sep 01, 2021, 07:32 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Aug 31, 2021 | Option Exercise | $18.93 | 24,800 | 469,374 | 24,800 | Sep 01, 2021, 07:30 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Aug 30, 2021 | Option Exercise | $19.27 | 5,200 | 100,204 | 5,200 | Sep 01, 2021, 07:30 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Aug 31, 2021 | Sale | $160.22 | 24,800 | 3,973,456 | 0 | Sep 01, 2021, 07:30 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Aug 30, 2021 | Sale | $155.78 | 5,200 | 810,082 | 4,496 | Sep 01, 2021, 07:30 PM |
| LEONARD JOHN M | President and CEO | Aug 23, 2021 | Option Exercise | $13.40 | 27,139 | 363,663 | 746,444 | Aug 25, 2021, 04:14 PM |
| LEONARD JOHN M | President and CEO | Aug 23, 2021 | Sale | $152.01 | 27,139 | 4,125,416 | 727,570 | Aug 25, 2021, 04:14 PM |
| LEONARD JOHN M | President and CEO | Aug 19, 2021 | Option Exercise | $13.40 | 22,682 | 303,939 | 741,987 | Aug 20, 2021, 06:14 PM |
| LEONARD JOHN M | President and CEO | Aug 19, 2021 | Sale | $151.28 | 22,682 | 3,431,398 | 732,261 | Aug 20, 2021, 06:14 PM |
| Lebwohl David | EVP, Chief Medical Officer | Aug 09, 2021 | Option Exercise | $12.62 | 2,400 | 30,288 | 3,191 | Aug 11, 2021, 04:50 PM |
| Lebwohl David | EVP, Chief Medical Officer | Aug 09, 2021 | Sale | $164.05 | 2,400 | 393,720 | 791 | Aug 11, 2021, 04:50 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Aug 04, 2021 | Option Exercise | $13.40 | 26,000 | 348,400 | 28,391 | Aug 06, 2021, 06:19 PM |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Aug 04, 2021 | Sale | $138.24 | 26,000 | 3,594,357 | 26,920 | Aug 06, 2021, 06:19 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Aug 05, 2021 | Option Exercise | $19.27 | 20,000 | 385,400 | 20,000 | Aug 06, 2021, 06:17 PM |
| Goddard Glenn | EVP, Chief Financial Officer | Aug 05, 2021 | Sale | $151.05 | 20,000 | 3,021,056 | 10,098 | Aug 06, 2021, 06:17 PM |
| FORMELA JEAN FRANCOIS | Director | Apr 29, 2021 | Sale | $85.43 | 4,513 | 385,546 | 765,101 | Apr 30, 2021, 08:55 PM |
| FORMELA JEAN FRANCOIS | Director | Apr 28, 2021 | Sale | $85.56 | 131,926 | 11,287,893 | 799,354 | Apr 28, 2021, 07:51 PM |
| FORMELA JEAN FRANCOIS | Director | Apr 27, 2021 | Sale | $86.22 | 210,230 | 18,125,992 | 1,032,056 | Apr 28, 2021, 07:51 PM |
| FORMELA JEAN FRANCOIS | Director | Apr 26, 2021 | Sale | $84.93 | 806 | 68,454 | 1,111,770 | Apr 28, 2021, 07:51 PM |
| LEONARD JOHN M | President and CEO | Apr 13, 2021 | Option Exercise | $11.16 | 25,937 | 289,506 | 719,305 | Apr 15, 2021, 08:50 PM |
| FORMELA JEAN FRANCOIS | Director | Apr 05, 2021 | Sale | $84.98 | 800 | 67,984 | 1,112,576 | Apr 07, 2021, 02:14 PM |
| Rivera Jose E | EVP, General Counsel | Apr 01, 2021 | Option Exercise | $12.51 | 97,001 | 1,213,537 | 178,077 | Apr 02, 2021, 08:42 PM |
| Rivera Jose E | EVP, General Counsel | Apr 01, 2021 | Sale | $82.46 | 50,455 | 4,160,559 | 176,112 | Apr 02, 2021, 08:42 PM |
| FORMELA JEAN FRANCOIS | Director | Feb 26, 2021 | Sale | $60.29 | 501,945 | 30,262,716 | 1,113,376 | Mar 01, 2021, 01:59 PM |
| Rivera Jose E | EVP, General Counsel | Feb 09, 2021 | Option Exercise | $18.30 | 21,000 | 384,195 | 129,409 | Feb 09, 2021, 08:38 PM |
| Rivera Jose E | EVP, General Counsel | Feb 09, 2021 | Sale | $75.00 | 11,489 | 861,675 | 117,920 | Feb 09, 2021, 08:38 PM |
| LEONARD JOHN M | President and CEO | Feb 09, 2021 | Option Exercise | $6.83 | 56,718 | 387,384 | 688,579 | Feb 09, 2021, 08:36 PM |
| LEONARD JOHN M | President and CEO | Feb 05, 2021 | Option Exercise | $13.40 | 40,000 | 536,000 | 654,803 | Feb 09, 2021, 08:36 PM |
| LEONARD JOHN M | President and CEO | Feb 09, 2021 | Sale | $75.00 | 28,043 | 2,103,225 | 660,536 | Feb 09, 2021, 08:36 PM |
| LEONARD JOHN M | President and CEO | Feb 05, 2021 | Sale | $67.66 | 22,942 | 1,552,185 | 646,760 | Feb 09, 2021, 08:36 PM |
| LEONARD JOHN M | President and CEO | Feb 01, 2021 | Option Exercise | $13.69 | 200,000 | 2,737,600 | 598,814 | Feb 03, 2021, 09:39 PM |
| LEONARD JOHN M | President and CEO | Feb 03, 2021 | Option Exercise | $17.68 | 117,060 | 2,069,793 | 651,661 | Feb 03, 2021, 09:39 PM |
| LEONARD JOHN M | President and CEO | Feb 03, 2021 | Sale | $72.54 | 67,856 | 4,922,490 | 614,803 | Feb 03, 2021, 09:39 PM |
| LEONARD JOHN M | President and CEO | Feb 01, 2021 | Sale | $64.00 | 109,889 | 7,032,905 | 587,714 | Feb 03, 2021, 09:39 PM |
| Rivera Jose E | EVP, General Counsel | Feb 01, 2021 | Option Exercise | $9.68 | 109,000 | 1,054,620 | 121,686 | Feb 03, 2021, 09:38 PM |
| Rivera Jose E | EVP, General Counsel | Feb 01, 2021 | Sale | $63.99 | 54,659 | 3,497,903 | 115,069 | Feb 03, 2021, 09:38 PM |
| Cohen Fred E | Director | Jan 20, 2021 | Option Exercise | $13.78 | 20,000 | 275,600 | 30,000 | Jan 22, 2021, 04:22 PM |
| LEONARD JOHN M | President and CEO | Jan 05, 2021 | Sale | $55.86 | 6,239 | 348,511 | 475,488 | Jan 05, 2021, 09:24 PM |
| SCHIERMEIER ANDREW | EVP, Chief Operating Officer | Jan 05, 2021 | Sale | $55.86 | 1,377 | 76,919 | 16,656 | Jan 05, 2021, 08:58 PM |
| Rivera Jose E | EVP, General Counsel | Jan 05, 2021 | Sale | $55.86 | 2,078 | 116,077 | 51,990 | Jan 05, 2021, 08:55 PM |
| SCHIERMEIER ANDREW | EVP, Chief Operating Officer | Dec 30, 2020 | Option Exercise | $13.48 | 1,500 | 20,220 | 12,673 | Jan 04, 2021, 09:03 PM |
| KARSEN PERRY A | Director | Dec 17, 2020 | Option Exercise | $18.45 | 88,764 | 1,637,842 | 93,764 | Dec 18, 2020, 04:29 PM |
| KARSEN PERRY A | Director | Dec 17, 2020 | Sale | $53.55 | 88,764 | 4,753,680 | 71,786 | Dec 18, 2020, 04:29 PM |
| Rivera Jose E | EVP, General Counsel | Dec 01, 2020 | Option Exercise | $13.88 | 5,000 | 69,400 | 52,072 | Dec 03, 2020, 06:42 PM |
| Rivera Jose E | EVP, General Counsel | Dec 01, 2020 | Sale | $38.21 | 3,364 | 128,525 | 50,487 | Dec 03, 2020, 06:42 PM |
| LEONARD JOHN M | President and CEO | Nov 27, 2020 | Option Exercise | $16.17 | 35,000 | 566,100 | 487,352 | Nov 27, 2020, 09:00 PM |
| LEONARD JOHN M | President and CEO | Nov 27, 2020 | Sale | $38.57 | 35,000 | 1,350,000 | 467,352 | Nov 27, 2020, 09:00 PM |
| LEONARD JOHN M | President and CEO | Nov 25, 2020 | Option Exercise | $6.83 | 50,000 | 341,500 | 517,352 | Nov 25, 2020, 08:02 PM |
| LEONARD JOHN M | President and CEO | Nov 25, 2020 | Sale | $36.00 | 50,000 | 1,800,000 | 467,352 | Nov 25, 2020, 08:02 PM |
| LEONARD JOHN M | President and CEO | Nov 16, 2020 | Option Exercise | $14.58 | 20,000 | 291,600 | 487,352 | Nov 18, 2020, 07:56 PM |
| LEONARD JOHN M | President and CEO | Nov 16, 2020 | Sale | $34.00 | 20,000 | 680,000 | 467,352 | Nov 18, 2020, 07:56 PM |
| Rivera Jose E | EVP, General Counsel | Nov 18, 2020 | Option Exercise | $18.30 | 848 | 15,518 | 47,696 | Nov 18, 2020, 07:55 PM |
| Rivera Jose E | EVP, General Counsel | Nov 16, 2020 | Option Exercise | $7.44 | 10,562 | 78,585 | 52,315 | Nov 18, 2020, 07:55 PM |
| Rivera Jose E | EVP, General Counsel | Nov 16, 2020 | Sale | $34.29 | 6,029 | 206,728 | 50,295 | Nov 18, 2020, 07:55 PM |
| Rivera Jose E | EVP, General Counsel | Nov 18, 2020 | Sale | $35.00 | 624 | 21,840 | 47,072 | Nov 18, 2020, 07:55 PM |
| Rivera Jose E | EVP, General Counsel | Nov 04, 2020 | Option Exercise | $13.88 | 5,000 | 69,400 | 45,679 | Nov 06, 2020, 04:41 PM |
| Rivera Jose E | EVP, General Counsel | Nov 04, 2020 | Sale | $28.00 | 3,364 | 94,192 | 42,315 | Nov 06, 2020, 04:41 PM |
| LEONARD JOHN M | President and CEO | Nov 04, 2020 | Option Exercise | $6.83 | 50,000 | 341,500 | 517,352 | Nov 06, 2020, 04:38 PM |
| LEONARD JOHN M | President and CEO | Nov 04, 2020 | Sale | $26.00 | 50,000 | 1,300,000 | 467,352 | Nov 06, 2020, 04:38 PM |
| Rivera Jose E | EVP, General Counsel | Oct 15, 2020 | Option Exercise | $6.83 | 10,000 | 68,300 | 46,294 | Oct 16, 2020, 08:58 PM |
| Rivera Jose E | EVP, General Counsel | Oct 15, 2020 | Sale | $24.20 | 5,615 | 135,883 | 40,835 | Oct 16, 2020, 08:58 PM |
| LEONARD JOHN M | President and CEO | Oct 07, 2020 | Option Exercise | $6.83 | 5,000 | 34,150 | 472,352 | Oct 09, 2020, 04:14 PM |
| LEONARD JOHN M | President and CEO | Oct 07, 2020 | Sale | $21.83 | 5,000 | 109,150 | 467,352 | Oct 09, 2020, 04:14 PM |
| Rivera Jose E | EVP, General Counsel | Sep 15, 2020 | Option Exercise | $6.83 | 10,000 | 68,300 | 41,909 | Sep 17, 2020, 04:55 PM |
| Rivera Jose E | EVP, General Counsel | Sep 15, 2020 | Sale | $21.04 | 5,615 | 118,140 | 36,294 | Sep 17, 2020, 04:55 PM |
| LEONARD JOHN M. | President and CEO | Sep 01, 2020 | Option Exercise | $6.83 | 5,000 | 34,150 | 472,352 | Sep 03, 2020, 04:15 PM |
| LEONARD JOHN M. | President and CEO | Sep 01, 2020 | Sale | $21.83 | 5,000 | 109,150 | 467,352 | Sep 03, 2020, 04:15 PM |
| Rivera Jose E | EVP, General Counsel | Aug 18, 2020 | Option Exercise | $6.83 | 10,000 | 68,300 | 37,524 | Aug 20, 2020, 04:13 PM |
| Rivera Jose E | EVP, General Counsel | Aug 18, 2020 | Sale | $21.00 | 5,615 | 117,915 | 31,909 | Aug 20, 2020, 04:13 PM |
| LEONARD JOHN M. | President and CEO | Aug 06, 2020 | Option Exercise | $6.83 | 5,000 | 34,150 | 472,352 | Aug 07, 2020, 07:29 PM |
| LEONARD JOHN M. | President and CEO | Aug 06, 2020 | Sale | $21.83 | 5,000 | 109,150 | 467,352 | Aug 07, 2020, 07:29 PM |
| Rivera Jose E | EVP, General Counsel | Jul 15, 2020 | Option Exercise | $6.83 | 10,000 | 68,300 | 33,139 | Jul 17, 2020, 04:18 PM |
| Rivera Jose E | EVP, General Counsel | Jul 15, 2020 | Sale | $22.70 | 5,615 | 127,461 | 27,524 | Jul 17, 2020, 04:18 PM |
| LEONARD JOHN M. | President and CEO | Jul 01, 2020 | Option Exercise | $6.83 | 5,000 | 34,150 | 472,352 | Jul 02, 2020, 04:10 PM |
| LEONARD JOHN M. | President and CEO | Jul 01, 2020 | Sale | $21.83 | 5,000 | 109,150 | 467,352 | Jul 02, 2020, 04:10 PM |
| Rivera Jose E | EVP, General Counsel | Jun 16, 2020 | Option Exercise | $6.83 | 10,000 | 68,300 | 27,897 | Jun 18, 2020, 05:00 PM |
| Rivera Jose E | EVP, General Counsel | Jun 16, 2020 | Sale | $21.00 | 5,615 | 117,915 | 22,282 | Jun 18, 2020, 05:00 PM |
| LEONARD JOHN M. | President and CEO | Jun 03, 2020 | Option Exercise | $6.83 | 5,000 | 34,150 | 472,352 | Jun 05, 2020, 05:18 PM |
| LEONARD JOHN M. | President and CEO | Jun 03, 2020 | Sale | $21.83 | 5,000 | 109,150 | 467,352 | Jun 05, 2020, 05:18 PM |
| Rivera Jose E | EVP, General Counsel | May 26, 2020 | Option Exercise | $6.83 | 10,000 | 68,300 | 285,722 | May 28, 2020, 05:23 PM |
| Rivera Jose E | EVP, General Counsel | May 26, 2020 | Sale | $21.21 | 5,615 | 119,094 | 280,107 | May 28, 2020, 05:23 PM |
| SCHIERMEIER ANDREW | EVP, Dev and Corp Strategy | Mar 06, 2019 | Buy | $15.72 | 7,500 | 117,875 | 7,500 | Mar 12, 2019, 04:38 PM |
| Cohen Fred E | Director | Mar 01, 2019 | Option Exercise | $16.89 | 10,000 | 168,936 | 10,000 | Mar 05, 2019, 12:00 AM |
| FORMELA JEAN FRANCOIS | Director | Jul 16, 2018 | Sale | $31.17 | 6,686 | 208,397 | 1,402 | Jul 18, 2018, 08:40 AM |
| FORMELA JEAN FRANCOIS | Director | Jun 19, 2018 | Sale | $27.96 | 6,686 | 186,908 | 1,400 | Jun 20, 2018, 12:03 PM |
| FORMELA JEAN FRANCOIS | Director | May 16, 2018 | Sale | $25.04 | 6,686 | 167,389 | 0 | May 17, 2018, 10:47 AM |
| LEONARD JOHN M. | President and CEO | May 14, 2018 | Sale | $24.00 | 8,400 | 201,600 | 0 | May 15, 2018, 08:43 PM |
| Bell Graeme | EVP, Chief Financial Officer | Mar 28, 2018 | Option Exercise | $13.48 | 8,000 | 107,840 | 21,400 | Mar 30, 2018, 10:20 AM |
| DORSA CAROLINE | Director | Mar 23, 2018 | Option Exercise | $24.05 | 410 | 9,860 | 5,410 | Mar 26, 2018, 05:12 PM |
| FORMELA JEAN FRANCOIS | Director | Mar 20, 2018 | Sale | $23.87 | 39,245 | 936,743 | 36,628 | Mar 22, 2018, 01:43 PM |
| Caribou Biosciences, Inc. | 10% Owner | Jan 29, 2018 | Sale | $26.78 | 550,645 | 14,746,273 | 3,994,355 | Jan 30, 2018, 05:28 PM |
| Novartis Institutes for BioMedical Research, Inc. | 10% Owner | Dec 12, 2017 | Sale | $18.30 | 1,523,000 | 27,870,899 | 4,129,903 | Dec 14, 2017, 12:19 PM |
| Bermingham Nessan | President & CEO | Dec 07, 2017 | Sale | $21.14 | 131,140 | 2,771,867 | 579,959 | Dec 08, 2017, 05:27 PM |
| Bermingham Nessan | President & CEO | Dec 06, 2017 | Sale | $20.34 | 111,500 | 2,268,001 | 696,000 | Dec 08, 2017, 05:27 PM |
| Bermingham Nessan | President & CEO | Dec 08, 2017 | Sale | $20.82 | 94,143 | 1,960,151 | 458,250 | Dec 08, 2017, 05:27 PM |
| Bell Graeme | EVP, Chief Financial Officer | Nov 03, 2017 | Option Exercise | $22.04 | 5,000 | 110,217 | 13,400 | Nov 03, 2017, 11:54 AM |
| FORMELA JEAN FRANCOIS | Director | Jul 10, 2017 | Sale | $16.17 | 40,000 | 646,888 | 3,659,788 | Jul 11, 2017, 05:40 PM |
| FORMELA JEAN FRANCOIS | Director | Jul 07, 2017 | Sale | $16.77 | 30,000 | 502,992 | 3,699,788 | Jul 11, 2017, 05:40 PM |
| FORMELA JEAN FRANCOIS | Director | Jul 11, 2017 | Sale | $16.07 | 80,000 | 1,285,560 | 3,579,788 | Jul 11, 2017, 05:40 PM |
| Atlas Venture Fund IX, L.P. | 10% Owner | Jul 11, 2017 | Sale | $16.07 | 80,000 | 1,285,560 | 3,579,788 | Jul 11, 2017, 05:37 PM |
| Atlas Venture Fund IX, L.P. | 10% Owner | Jul 10, 2017 | Sale | $16.17 | 40,000 | 646,888 | 3,659,788 | Jul 11, 2017, 05:37 PM |
| Atlas Venture Fund IX, L.P. | 10% Owner | Jul 07, 2017 | Sale | $16.77 | 30,000 | 502,992 | 3,699,788 | Jul 11, 2017, 05:37 PM |
| DORSA CAROLINE | Director | Jun 02, 2017 | Option Exercise | $12.42 | 5,000 | 62,100 | 5,000 | Jun 05, 2017, 08:03 AM |
| KARSEN PERRY A | Director | Jun 01, 2017 | Option Exercise | $11.98 | 5,000 | 59,925 | 5,000 | Jun 05, 2017, 08:01 AM |
| Bell Graeme | EVP, Chief Financial Officer | Jun 02, 2017 | Option Exercise | $12.37 | 8,400 | 103,938 | 8,400 | Jun 05, 2017, 07:59 AM |
| LEONARD JOHN M. | EVP, R&D | Jun 01, 2017 | Option Exercise | $12.06 | 8,400 | 101,322 | 8,400 | Jun 05, 2017, 07:55 AM |
| Bermingham Nessan | President & CEO | Jun 01, 2017 | Option Exercise | $11.95 | 8,400 | 100,379 | 795,033 | Jun 05, 2017, 07:53 AM |
| Atlas Venture Associates IX, L.P. | 10% Owner | Mar 10, 2017 | Sale | $14.06 | 5,504 | 77,410 | 0 | Mar 13, 2017, 10:39 AM |
| Atlas Venture Associates IX, L.P. | 10% Owner | Mar 09, 2017 | Sale | $13.85 | 15,628 | 216,432 | 5,504 | Mar 13, 2017, 10:39 AM |
| FORMELA JEAN FRANCOIS | Director | Mar 10, 2017 | Sale | $14.06 | 5,504 | 77,410 | 0 | Mar 13, 2017, 10:34 AM |
| FORMELA JEAN FRANCOIS | Director | Mar 09, 2017 | Sale | $13.85 | 15,628 | 216,432 | 5,504 | Mar 13, 2017, 10:34 AM |
| ORBIMED ADVISORS LLC | Director | May 11, 2016 | Buy | $18.00 | 250,000 | 4,500,000 | 2,662,180 | May 13, 2016, 04:58 PM |
| Temasek Holdings (Private) Ltd | 10% Owner | May 11, 2016 | Buy | $18.00 | 300,000 | 5,400,000 | 790,527 | May 13, 2016, 06:15 AM |
| Novartis Institutes for BioMedical Research, Inc. | 10% Owner | May 11, 2016 | Buy | $18.00 | 277,777 | 4,999,986 | 5,573,658 | May 11, 2016, 06:57 PM |
| GORDON CARL L | Director | May 11, 2016 | Buy | $18.00 | 250,000 | 4,500,000 | 2,662,180 | May 11, 2016, 06:36 PM |
| BAKER BROS. ADVISORS LP | Former 10% owner | May 11, 2016 | Buy | $18.00 | 200,000 | 3,600,000 | 976,214 | May 11, 2016, 04:25 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Clark Eliana | EVP, Chief Technical Officer | 07/01/2024 | 9,287 |
| Verwiel Frank | Director | 06/17/2024 | 37,625 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 01/08/2024 | 65,682 |
| LEONARD JOHN M | President and CEO | 01/03/2024 | 566,310 |
| Lebwohl David | EVP, Chief Medical Officer | 01/03/2024 | 172,135 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 01/03/2024 | 162,973 |
| Goddard Glenn | EVP, Chief Financial Officer | 01/03/2024 | 158,053 |
| Hicks Derek | EVP, Chief Business Officer | 01/03/2024 | 114,216 |
| BASTA JAMES | EVP, General Counsel | 01/03/2024 | 112,095 |
| Clark Eliana | EVP, Chief Technical Officer | 01/03/2024 | 135,954 |
| Bhanji Muna | Director | 10/31/2023 | 6,333 |
| Bhanji Muna | Director | 07/31/2023 | 11,217 |
| Bhanji Muna | Director | 07/06/2023 | 73,373 |
| Clark Eliana | EVP, Chief Technical Officer | 07/03/2023 | 14,584 |
| Clark Eliana | EVP, Chief Technical Officer | 06/20/2023 | 61,350 |
| Clark Eliana | EVP, Chief Technical Officer | 06/20/2023 | 225,000 |
| BASTA JAMES | EVP, General Counsel | 03/02/2023 | 47,741 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 01/05/2023 | 89,659 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 01/04/2023 | 93,323 |
| LEONARD JOHN M | President and CEO | 01/04/2023 | 248,302 |
| Hicks Derek | EVP, Chief Business Officer | 01/04/2023 | 67,425 |
| Lebwohl David | EVP, Chief Medical Officer | 01/04/2023 | 95,779 |
| Goddard Glenn | EVP, Chief Financial Officer | 01/04/2023 | 90,309 |
| Clark Eliana | EVP, Chief Technical Officer | 01/04/2023 | 62,959 |
| Clark Eliana | EVP, Chief Technical Officer | 01/03/2023 | 7,965 |
| Clark Eliana | EVP, Chief Technical Officer | 07/01/2022 | 5,433 |
| BASTA JAMES | EVP, General Counsel | 01/04/2023 | 42,345 |
| LEONARD JOHN M | President and CEO | 01/01/2022 | 279,852 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 01/01/2022 | 128,863 |
| Lebwohl David | EVP, Chief Medical Officer | 01/01/2022 | 117,964 |
| Goddard Glenn | EVP, Chief Financial Officer | 01/01/2022 | 113,699 |
| Lebwohl David | EVP, Chief Medical Officer | 11/05/2021 | 30,288 |
| Lebwohl David | EVP, Chief Medical Officer | 11/05/2021 | 318,535 |
| Lebwohl David | EVP, Chief Medical Officer | 10/14/2021 | 30,288 |
| Lebwohl David | EVP, Chief Medical Officer | 10/14/2021 | 308,249 |
| Crowley John F | Director | 10/11/2021 | 47,075 |
| Crowley John F | Director | 10/11/2021 | 298,875 |
| Crowley John F | Director | 10/05/2021 | 188,300 |
| Crowley John F | Director | 10/05/2021 | 1,305,391 |
| Lebwohl David | EVP, Chief Medical Officer | 09/24/2021 | 99,988 |
| Lebwohl David | EVP, Chief Medical Officer | 09/21/2021 | 30,288 |
| Lebwohl David | EVP, Chief Medical Officer | 09/21/2021 | 359,544 |
| Goddard Glenn | EVP, Chief Financial Officer | 09/07/2021 | 50,768 |
| Goddard Glenn | EVP, Chief Financial Officer | 09/07/2021 | 627,178 |
| LEONARD JOHN M | President and CEO | 08/31/2021 | 551,605 |
| LEONARD JOHN M | President and CEO | 08/30/2021 | 552,031 |
| LEONARD JOHN M | President and CEO | 09/01/2021 | 967,000 |
| LEONARD JOHN M | President and CEO | 08/30/2021 | 6,051,353 |
| LEONARD JOHN M | President and CEO | 09/01/2021 | 7,604,950 |
| LEONARD JOHN M | President and CEO | 08/31/2021 | 5,864,115 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 08/30/2021 | 1,359,300 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 08/30/2021 | 15,018,055 |
| Lebwohl David | EVP, Chief Medical Officer | 08/30/2021 | 30,288 |
| Lebwohl David | EVP, Chief Medical Officer | 08/30/2021 | 379,300 |
| Goddard Glenn | EVP, Chief Financial Officer | 08/31/2021 | 469,374 |
| Goddard Glenn | EVP, Chief Financial Officer | 08/30/2021 | 100,204 |
| Goddard Glenn | EVP, Chief Financial Officer | 08/31/2021 | 3,973,456 |
| Goddard Glenn | EVP, Chief Financial Officer | 08/30/2021 | 810,082 |
| LEONARD JOHN M | President and CEO | 08/23/2021 | 363,663 |
| LEONARD JOHN M | President and CEO | 08/23/2021 | 4,125,416 |
| LEONARD JOHN M | President and CEO | 08/19/2021 | 303,939 |
| LEONARD JOHN M | President and CEO | 08/19/2021 | 3,431,398 |
| Lebwohl David | EVP, Chief Medical Officer | 08/09/2021 | 30,288 |
| Lebwohl David | EVP, Chief Medical Officer | 08/09/2021 | 393,720 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 08/04/2021 | 348,400 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 08/04/2021 | 3,594,357 |
| Goddard Glenn | EVP, Chief Financial Officer | 08/05/2021 | 385,400 |
| Goddard Glenn | EVP, Chief Financial Officer | 08/05/2021 | 3,021,056 |
| FORMELA JEAN FRANCOIS | Director | 04/29/2021 | 385,546 |
| FORMELA JEAN FRANCOIS | Director | 04/28/2021 | 11,287,893 |
| FORMELA JEAN FRANCOIS | Director | 04/27/2021 | 18,125,992 |
| FORMELA JEAN FRANCOIS | Director | 04/26/2021 | 68,454 |
| LEONARD JOHN M | President and CEO | 04/13/2021 | 289,506 |
| FORMELA JEAN FRANCOIS | Director | 04/05/2021 | 67,984 |
| Rivera Jose E | EVP, General Counsel | 04/01/2021 | 1,213,537 |
| Rivera Jose E | EVP, General Counsel | 04/01/2021 | 4,160,559 |
| FORMELA JEAN FRANCOIS | Director | 02/26/2021 | 30,262,716 |
| Rivera Jose E | EVP, General Counsel | 02/09/2021 | 384,195 |
| Rivera Jose E | EVP, General Counsel | 02/09/2021 | 861,675 |
| LEONARD JOHN M | President and CEO | 02/09/2021 | 387,384 |
| LEONARD JOHN M | President and CEO | 02/05/2021 | 536,000 |
| LEONARD JOHN M | President and CEO | 02/09/2021 | 2,103,225 |
| LEONARD JOHN M | President and CEO | 02/05/2021 | 1,552,185 |
| LEONARD JOHN M | President and CEO | 02/01/2021 | 2,737,600 |
| LEONARD JOHN M | President and CEO | 02/03/2021 | 2,069,793 |
| LEONARD JOHN M | President and CEO | 02/03/2021 | 4,922,490 |
| LEONARD JOHN M | President and CEO | 02/01/2021 | 7,032,905 |
| Rivera Jose E | EVP, General Counsel | 02/01/2021 | 1,054,620 |
| Rivera Jose E | EVP, General Counsel | 02/01/2021 | 3,497,903 |
| Cohen Fred E | Director | 01/20/2021 | 275,600 |
| LEONARD JOHN M | President and CEO | 01/05/2021 | 348,511 |
| SCHIERMEIER ANDREW | EVP, Chief Operating Officer | 01/05/2021 | 76,919 |
| Rivera Jose E | EVP, General Counsel | 01/05/2021 | 116,077 |
| SCHIERMEIER ANDREW | EVP, Chief Operating Officer | 12/30/2020 | 20,220 |
| KARSEN PERRY A | Director | 12/17/2020 | 1,637,842 |
| KARSEN PERRY A | Director | 12/17/2020 | 4,753,680 |
| Rivera Jose E | EVP, General Counsel | 12/01/2020 | 69,400 |
| Rivera Jose E | EVP, General Counsel | 12/01/2020 | 128,525 |
| LEONARD JOHN M | President and CEO | 11/27/2020 | 566,100 |
| LEONARD JOHN M | President and CEO | 11/27/2020 | 1,350,000 |
| LEONARD JOHN M | President and CEO | 11/25/2020 | 341,500 |
| LEONARD JOHN M | President and CEO | 11/25/2020 | 1,800,000 |
| LEONARD JOHN M | President and CEO | 11/16/2020 | 291,600 |
| LEONARD JOHN M | President and CEO | 11/16/2020 | 680,000 |
| Rivera Jose E | EVP, General Counsel | 11/18/2020 | 15,518 |
| Rivera Jose E | EVP, General Counsel | 11/16/2020 | 78,585 |
| Rivera Jose E | EVP, General Counsel | 11/16/2020 | 206,728 |
| Rivera Jose E | EVP, General Counsel | 11/18/2020 | 21,840 |
| Rivera Jose E | EVP, General Counsel | 11/04/2020 | 69,400 |
| Rivera Jose E | EVP, General Counsel | 11/04/2020 | 94,192 |
| LEONARD JOHN M | President and CEO | 11/04/2020 | 341,500 |
| LEONARD JOHN M | President and CEO | 11/04/2020 | 1,300,000 |
| Rivera Jose E | EVP, General Counsel | 10/15/2020 | 68,300 |
| Rivera Jose E | EVP, General Counsel | 10/15/2020 | 135,883 |
| LEONARD JOHN M | President and CEO | 10/07/2020 | 34,150 |
| LEONARD JOHN M | President and CEO | 10/07/2020 | 109,150 |
| Rivera Jose E | EVP, General Counsel | 09/15/2020 | 68,300 |
| Rivera Jose E | EVP, General Counsel | 09/15/2020 | 118,140 |
| LEONARD JOHN M. | President and CEO | 09/01/2020 | 34,150 |
| LEONARD JOHN M. | President and CEO | 09/01/2020 | 109,150 |
| Rivera Jose E | EVP, General Counsel | 08/18/2020 | 68,300 |
| Rivera Jose E | EVP, General Counsel | 08/18/2020 | 117,915 |
| LEONARD JOHN M. | President and CEO | 08/06/2020 | 34,150 |
| LEONARD JOHN M. | President and CEO | 08/06/2020 | 109,150 |
| Rivera Jose E | EVP, General Counsel | 07/15/2020 | 68,300 |
| Rivera Jose E | EVP, General Counsel | 07/15/2020 | 127,461 |
| LEONARD JOHN M. | President and CEO | 07/01/2020 | 34,150 |
| LEONARD JOHN M. | President and CEO | 07/01/2020 | 109,150 |
| Rivera Jose E | EVP, General Counsel | 06/16/2020 | 68,300 |
| Rivera Jose E | EVP, General Counsel | 06/16/2020 | 117,915 |
| LEONARD JOHN M. | President and CEO | 06/03/2020 | 34,150 |
| LEONARD JOHN M. | President and CEO | 06/03/2020 | 109,150 |
| Rivera Jose E | EVP, General Counsel | 05/26/2020 | 68,300 |
| Rivera Jose E | EVP, General Counsel | 05/26/2020 | 119,094 |
| SCHIERMEIER ANDREW | EVP, Dev and Corp Strategy | 03/06/2019 | 117,875 |
| Cohen Fred E | Director | 03/01/2019 | 168,936 |
| FORMELA JEAN FRANCOIS | Director | 07/16/2018 | 208,397 |
| FORMELA JEAN FRANCOIS | Director | 06/19/2018 | 186,908 |
| FORMELA JEAN FRANCOIS | Director | 05/16/2018 | 167,389 |
| LEONARD JOHN M. | President and CEO | 05/14/2018 | 201,600 |
| Bell Graeme | EVP, Chief Financial Officer | 03/28/2018 | 107,840 |
| DORSA CAROLINE | Director | 03/23/2018 | 9,860 |
| FORMELA JEAN FRANCOIS | Director | 03/20/2018 | 936,743 |
| Caribou Biosciences, Inc. | 10% Owner | 01/29/2018 | 14,746,273 |
| Novartis Institutes for BioMedical Research, Inc. | 10% Owner | 12/12/2017 | 27,870,899 |
| Bermingham Nessan | President & CEO | 12/07/2017 | 2,771,867 |
| Bermingham Nessan | President & CEO | 12/06/2017 | 2,268,001 |
| Bermingham Nessan | President & CEO | 12/08/2017 | 1,960,151 |
| Bell Graeme | EVP, Chief Financial Officer | 11/03/2017 | 110,217 |
| FORMELA JEAN FRANCOIS | Director | 07/10/2017 | 646,888 |
| FORMELA JEAN FRANCOIS | Director | 07/07/2017 | 502,992 |
| FORMELA JEAN FRANCOIS | Director | 07/11/2017 | 1,285,560 |
| Atlas Venture Fund IX, L.P. | 10% Owner | 07/11/2017 | 1,285,560 |
| Atlas Venture Fund IX, L.P. | 10% Owner | 07/10/2017 | 646,888 |
| Atlas Venture Fund IX, L.P. | 10% Owner | 07/07/2017 | 502,992 |
| DORSA CAROLINE | Director | 06/02/2017 | 62,100 |
| KARSEN PERRY A | Director | 06/01/2017 | 59,925 |
| Bell Graeme | EVP, Chief Financial Officer | 06/02/2017 | 103,938 |
| LEONARD JOHN M. | EVP, R&D | 06/01/2017 | 101,322 |
| Bermingham Nessan | President & CEO | 06/01/2017 | 100,379 |
| Atlas Venture Associates IX, L.P. | 10% Owner | 03/10/2017 | 77,410 |
| Atlas Venture Associates IX, L.P. | 10% Owner | 03/09/2017 | 216,432 |
| FORMELA JEAN FRANCOIS | Director | 03/10/2017 | 77,410 |
| FORMELA JEAN FRANCOIS | Director | 03/09/2017 | 216,432 |
| ORBIMED ADVISORS LLC | Director | 05/11/2016 | 4,500,000 |
| Temasek Holdings (Private) Ltd | 10% Owner | 05/11/2016 | 5,400,000 |
| Novartis Institutes for BioMedical Research, Inc. | 10% Owner | 05/11/2016 | 4,999,986 |
| GORDON CARL L | Director | 05/11/2016 | 4,500,000 |
| BAKER BROS. ADVISORS LP | Former 10% owner | 05/11/2016 | 3,600,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN INTELLIA THERAPEUTICS, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ARK INVESTMENT MANAGEMENT LLC | 11,595,789 | 2.3% | 5.52% | Growth |
| BLACKROCK INC. | 9,597,607 | 0.00486% | 5.36% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 2,293,943 | 0.00451% | 12.21% | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 347,483 | 0.01% | 84.34% | Event Driven |
| ALPS ADVISORS INC | 75,237 | 0.01% | 11% | Other |
| TUDOR INVESTMENT CORP ET AL | 61,783 | 0.00708% | 30.14% | Event Driven, Other |
| RENAISSANCE TECHNOLOGIES LLC | 38,700 | 0.00147% | New | Other |
| D. E. SHAW & CO., INC. | 30,000 (Put) | 0.00063% | New | Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 30,000 (Call) | 0.00023% | 20% | Value |
CHANGE IN SHARES OUTSTANDING FOR INTELLIA THERAPEUTICS, INC.
STOCK BUYBACKS FOR INTELLIA THERAPEUTICS, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
5.56%
1Q
09/30/2023
7.74%
2Q
06/30/2023
8.30%
3Q
03/31/2023
8.81%
4Q
12/31/2022
17.53%
5Q
09/30/2022
25.58%
6Q
06/30/2022
25.95%
7Q
03/31/2022
27.76%
8Q
12/31/2021
28.34%
9Q
09/30/2021
29.57%
10Q
06/30/2021
40.11%
11Q
03/31/2021
42.15%
12Q
12/31/2020
55.81%
13Q
09/30/2020
62.55%
14Q
06/30/2020
78.95%
15Q
03/31/2020
89.15%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR INTELLIA THERAPEUTICS, INC.
LOADING...